Morpholine derivatives as potential agents for neurological manifestations of nervous system diseases
Open Access
- 28 March 2020
- journal article
- review article
- Published by ECO-Vector LLC in Pharmacy Formulas
- Vol. 2 (1) , 16-35
Abstract
Diseases of the nervous system, especially those of vascular, traumatic, and neurodegenerative nature, are characterized by high prevalence, disability and mortality rates, and therefore have a particularly big medical and social impact. Currently, pharmacotherapy options for these diseases are limited to a relatively small number of clinically proven drugs, which is largely due to the difficulties associated with the translation of preclinical studies results. This explains the essential importance of discovering and developing new drugs, both effective and safe, that could be used to reduce clinical manifestations of neurological disorders. The present review is aimed to give a detailed account of several biologically active derivatives of morpholine, a six-membered heterocyclic compound. As demonstrated by a number of in vitro and in vivo studies using cell and animal models, morpholine derivatives should be considered viable drug candidates for a broad range of neurological diseases.Keywords
This publication has 108 references indexed in Scilit:
- Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016The Lancet Neurology, 2019
- The Significance of Meaning: Why Do Over 90% of Behavioral Neuroscience Results Fail to Translate to Humans, and What Can We Do to Fix It?ILAR Journal, 2014
- Epidemiology of Dementias and Alzheimer’s DiseaseArchives of Medical Research, 2012
- SAR and biological evaluation of SEN12333/WAY-317538: Novel alpha 7 nicotinic acetylcholine receptor agonistBioorganic & Medicinal Chemistry, 2009
- Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030Neurology, 2007
- Neuroinflammatory perspectives on the two faces of Alzheimer?s diseaseJournal of Neural Transmission, 2004
- The Cannabinoid Receptor Agonist WIN 55,212-2 Regulates Glutamate Transmission in Rat Cerebral Cortex: an In Vivo and In Vitro StudyCerebral Cortex, 2001
- Oxazinin-1, -2 and -3 − A Novel Toxic Compound and Its Analogues from the Digestive Glands ofMytilus galloprovincialisEuropean Journal of Organic Chemistry, 2000
- Polygonapholine, an alkaloid with a novel skeleton, isolated from Polygonatum alte-lobatumTetrahedron, 1997
- Aromatic alkaloids from the marine sponge Chelonaplysilla spThe Journal of Organic Chemistry, 1991